Literature DB >> 6489430

Pharmacokinetics and bioavailability of digitoxin by a specific assay.

R T MacFarland, F I Marcus, P E Fenster, P E Graves, D Perrier.   

Abstract

The pharmacokinetics and bioavailability of digitoxin were examined in six normal human subjects using an assay that separates digitoxin from its metabolites. After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days. After oral administration, the elimination half-life was 5.8 days. The bioavailability was 81.5% using the specific assay. Using a non-specific, direct serum digitoxin radioimmunoassay the bioavailability was 98.0%. Assay of aqueous fractions from extracted serum samples indicated higher levels of water-soluble metabolites following oral compared to intravenous digitoxin administration. These findings suggest that previously reported values for digitoxin bioavailability using non-specific methods may be falsely elevated due to the presence of digitoxin metabolites in serum.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489430

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Correlation between inhibition of (Na+, K+)-membrane-ATPase and positive inotropic activity of cardenolides in isolated papillary muscles of guinea pig.

Authors:  H Flasch; N Heinz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-08       Impact factor: 3.000

2.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

3.  Studies on digitalis. VII. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites.

Authors:  L Storstein
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

4.  Comparison of digoxin with some digitoxin metabolites on cat heart lung preparation.

Authors:  H Böttcher; H Lüllmann; D Proppe
Journal:  Eur J Pharmacol       Date:  1973-04       Impact factor: 4.432

5.  Clinical use of a bio-assay of serum digitoxin activity.

Authors:  K Rasmussen; J Jervell; O Storstein
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

6.  Fate of orally administered 3H-digitoxin in man with special reference to the absorption.

Authors:  B Beermann; K Hellström; A Rosén
Journal:  Circulation       Date:  1971-06       Impact factor: 29.690

7.  Metabolism of digitoxin in man and its modification by spironolactone.

Authors:  K E Wirth; J C Frölich; J W Hollifield; F C Falkner; B S Sweetman; J A Oates
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

8.  Studies on digitalis. VIII. Digitoxin metabolism on a maintenance regimen and after a single dose.

Authors:  L Storstein
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

9.  Quantitative studies on acid hydrolysis of digitoxin.

Authors:  U Peters; C Funcke; T U Hausamen; W Staib
Journal:  Arzneimittelforschung       Date:  1978

10.  Quantitation of digitoxin and the bis- and monodigitoxosides of digitoxigenin in serum.

Authors:  P E Graves; D Perrier; F I Marcus
Journal:  J Chromatogr       Date:  1983-12-09
View more
  3 in total

Review 1.  Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations.

Authors:  A D Mooradian
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

2.  Bioavailability of the bis- and monodigitoxosides of digitoxigenin.

Authors:  P E Fenster; R T MacFarland; P E Graves; D Perrier; F I Marcus
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Digitoxin and its metabolites in patients with liver cirrhosis.

Authors:  A Nokhodian; S R Santos; W Kirch
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.